Nuvectis Pharma, Inc. (NVCT)

6,91 +0,15 (+2,22%) Ab 10:30AM EDT. Markt geöffnet.

Nuvectis Pharma, Inc.

1 Bridge Plaza
Suite 275
Fort Lee, NJ 07024
United States
201 614 3150
https://www.nuvectis.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 13

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Ron Bentsur M.B.A.	Co-Founder, Chairman, CEO & President	851,61k	N/A	1966
Dr. Enrique Poradosu Ph.D.	Co-Founder, Executive VP, Chief Scientific & Business Officer	549,07k	N/A	1967
Mr. Shay Shemesh	Co-Founder, Executive VP, Chief Development & Operations Officer	529,27k	N/A	1984

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Corporate Governance

Nuvectis Pharma, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 9. Die grundlegenden Scores sind Audit: 8, Vorstand: 10, Shareholderrechte: 6, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.